These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 28609761

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Pancreatic Neuroendocrine Neoplasms (p-NENs).
    Kolasińska-Ćwikła AD, Konsek SJ, Buscombe JR, Maciejkiewicz K, Cichocki A, Roszkowska-Purska K, Sawicki Ł, Tenderenda M, Cwikla JB.
    Nucl Med Rev Cent East Eur; 2019; 22(1):1-7. PubMed ID: 30276787
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Incremental diagnostic value and impact on patient management of somatostatin receptor scintigraphy with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors.
    Usmani S, Khan HA, Abdulla M, Ahmed N, abu Huda F, Marafi F, al Kandari F, al Mohannadi S, al Nafisi N.
    Med Princ Pract; 2011; 20(4):356-61. PubMed ID: 21576997
    [Abstract] [Full Text] [Related]

  • 11. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors.
    Schillaci O, Spanu A, Scopinaro F, Falchi A, Danieli R, Marongiu P, Pisu N, Madeddu G, Delle Fave G, Madeddu G.
    J Nucl Med; 2003 Mar; 44(3):359-68. PubMed ID: 12621001
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen.
    Adams S, Baum RP, Hertel A, Schumm-Dräger PM, Usadel KH, Hör G.
    Nucl Med Commun; 1998 Jul; 19(7):641-7. PubMed ID: 9853344
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Radioguided surgery with radiolabeled somatostatin analogs: not only in GEP-NETs.
    Cuccurullo V, Di Stasio GD, Mansi L.
    Nucl Med Rev Cent East Eur; 2017 Jul; 20(1):49-56. PubMed ID: 28218348
    [Abstract] [Full Text] [Related]

  • 19. Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors.
    Scherübl H, Bäder M, Fett U, Hamm B, Schmidt-Gayk H, Koppenhagen K, Dop FJ, Riecken EO, Wiedenmann B.
    Gastroenterology; 1993 Dec; 105(6):1705-9. PubMed ID: 7902821
    [Abstract] [Full Text] [Related]

  • 20. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.
    Bahri H, Laurence L, Edeline J, Leghzali H, Devillers A, Raoul JL, Cuggia M, Mesbah H, Clement B, Boucher E, Garin E.
    J Nucl Med; 2014 Nov; 55(11):1786-90. PubMed ID: 25286923
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.